Medicines optimisation · September 2026

Medicines optimisation projects for ICBs and PCNs

We place clinical pharmacists on defined medicines projects: best value DOAC reviews, price-per-unit and ghost generic work, lipid optimisation, cardiovascular risk (CVD), and the work in your ICB’s prescribing incentive scheme. Here is where every ICB in England stands, from NHSBSA’s prescribing data.

Tell us about a project

England in September 2026

Price-per-unit savings
£16,152,394in one month, across 1,299 PCNs
DOAC prescriptions that were best value
83%generic apixaban or rivaroxaban tablets
Other DOACs, cost per prescription
£43.89against £1.98 for best value
Ghost generics
£1,142,297at 2,305 practices, part of the price-per-unit savings

Your ICB

Compare all 36 ICBs

Ordered by price-per-unit savings for every 1,000 registered patients, most first.

Headline medicines optimisation figures for each ICB in England, September 2026
ICBPCNsPrice-per-unit savingsPer 1,000 patientsDOACs that were best value
Cornwall and the Isles of Scilly15£255,410£42076%
Lincolnshire14£325,411£39781%
Shropshire, Telford and Wrekin9£189,038£35686%
Devon30£448,717£35386%
Norfolk and Suffolk34£611,824£34268%
Staffordshire and Stoke-on-Trent25£384,330£32084%
West Yorkshire52£843,965£31984%
Leicester, Leicestershire and Rutland26£372,281£30778%
Black Country27£401,828£30487%
Humber and North Yorkshire45£547,723£30471%
Surrey and Sussex70£934,798£30184%
North East and North Cumbria66£950,912£29789%
Hampshire and Isle of Wight46£628,743£29384%
Herefordshire and Worcestershire15£227,375£27482%
Dorset18£218,289£26589%
Lancashire and South Cumbria45£484,805£26076%
Cheshire and Merseyside49£702,657£25580%
South Yorkshire29£381,492£25388%
Greater Manchester65£816,567£24986%
Essex40£490,311£24778%
Birmingham and Solihull36£396,868£24585%
Coventry and Warwickshire19£265,945£24086%
Thames Valley62£594,319£24084%
Bath and North East Somerset, Swindon and Wiltshire28£238,061£23673%
Kent and Medway45£474,220£23485%
Central East78£787,291£22583%
North East London48£510,401£21180%
South West London38£360,139£20881%
Somerset13£123,753£20684%
West and North London80£932,109£20191%
South East London37£413,115£19975%
Nottingham and Nottinghamshire24£237,574£18887%
Derby and Derbyshire17£208,892£18680%
Gloucestershire16£115,277£16591%
Bristol, North Somerset and South Gloucestershire21£166,024£15393%
Northamptonshire17£111,929£13291%

Source: NHSBSA English Prescribing Dataset, September 2026, Open Government Licence v3.0. How we work these out is below.

Project work

Get a delivery plan for your ICB

You know the data. The hard part is the time to do the work, practice by practice. Tell us the project and we’ll send a plan:

  • which practices to start with, and why
  • the work your prescribing scheme already pays practices for
  • how many pharmacist sessions it needs

Then we place clinical pharmacists to do it, for as long as the project needs.

The project (optional, pick any)
When would it start? (optional)

Your details go only to our clinical team. Please don’t include any patient details. Privacy notice.

How we work these out

Every figure is one month, September 2026, from NHSBSA’s English Prescribing Dataset for GP practices, as the data gives it: no saving is estimated or scaled up to a year.

  • Price-per-unit savings are what each practice would have saved if it had paid what the cheapest tenth of practices in England paid per unit for the same medicine, counted where the practice would save at least £10 on that medicine in the month. This is OpenPrescribing’s price-per-unit method. Some savings can’t be made, for example where a medicine is short or on price concession.
  • Ghost generics are generic medicines prescribed as one maker’s product instead of by their generic name, where England mostly prescribes the generic. They are part of the price-per-unit savings, not extra to them.
  • Best value DOACs are generic apixaban and generic rivaroxaban tablets, NHS England’s joint best value direct-acting oral anticoagulants. We show the cost per prescription of each group, not a saving: changing anyone’s anticoagulant is a clinical decision made with the patient after a review.

Sources

Contains public sector information licensed under the Open Government Licence v3.0.